Oct 4, 2017 by Motley Fool Staff4 Things You Need to Know About the FedThe Federal Reserve is about to see some changes. Here are some of the most important things to know about the potential candidates, and what might change going forward.
Oct 3, 2017 by Motley Fool Staff and Dylan LewisWhat's a Mini-IPO?The 2012 JOBS act made it easier for smaller companies to raise money from individual investors.
Oct 3, 2017 by Motley Fool StaffThe 3 Stocks on the MFM Team's Radar This WeekOur analysts explain why they recommend these companies for your portfolio.
Oct 3, 2017 by Motley Fool StaffRovio Entertainment Hits the Target With Its IPO PricingThe gaming company behind "Angry Birds” hit the market and shares held essentially flat.
Oct 3, 2017 by Motley Fool StaffWhy Thor Industries Shares Hit an All-Time High Last WeekThe RV-maker’s sales are surging, and the outlook is bright.
Oct 3, 2017 by Motley Fool StaffOnce Again, the Market Likes What McCormick Is CookingThe spice giant had a solid third quarter, and there’s no reason to expect its growth trend to change.
Oct 3, 2017 by Motley Fool Staff, Jason Moser, Chris Hill, Matthew Argersinger, and Aaron BushWhy Roku Shares Doubled 2 Days After the IPOThe initial share price for the streaming-media set-top box maker was $14. By the end of the week, shares traded as high as $29.80.
Oct 3, 2017 by Motley Fool StaffAmerican Airlines CEO Promises Permanent Profitability for His IndustryDoug Parker says airlines will never lose money again.
Oct 3, 2017 by Motley Fool StaffNike Trips and Falls to Near a 2-Year LowProfit fell 24% in its fiscal first quarter, and the smart money sees the pain continuing for a while.
Oct 3, 2017 by Motley Fool StaffWhy Impinj Is a Small-Cap Stock You Might Want to Take a Look AtImpinj provides RFID billions of stickers to retailers every year and can help companies gather massive amounts of new data about what their customers want.
Oct 3, 2017 by Motley Fool StaffIs This How Drugmakers Will Kill Biosimilars?Pfizer is accusing Johnson & Johnson of making unfair deals with insurers to reduce demand for Inflectra, its Remicade biosimilar.
Oct 3, 2017 by Motley Fool StaffAfter Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?The biotech's shares lost more than 70% of their value after intepirdine failed in a phase III trail.
Oct 3, 2017 by Motley Fool StaffDoes Walt Disney Have What It Takes to Go Head to Head Against Netflix?The leading entertainment company is ending its deal with Netflix in order to take the reins on distribution.
Oct 2, 2017 by Motley Fool StaffWalt Disney Prepares to Launch Its ESPN Streaming Service With 10,000 Live EventsThe Mouse House is taking on Netflix, Hulu, and other paid offerings as management looks to the future of content distribution.
Oct 2, 2017 by Motley Fool StaffWhy Paycom Should Be on Your Investing RadarPaycom is changing the game in the long-static world of human resources and cashing in on explosive growth as a result.
Oct 2, 2017 by Motley Fool StaffWhy Alarm.com Should Be on Your RadarAlarm.com is growing at an incredible clip by bringing home security into the age of the Internet of Things.
Oct 2, 2017 by Motley Fool StaffAn Introduction to Small-Cap StocksHere are the most important things investors need to know about small-cap stocks before buying them.
Oct 2, 2017 by Motley Fool StaffKohl's Deepens Its Unlikely Partnership With AmazonThe two retailers are working together in several ways, but not every company has benefited from previous collaborations with the e-commerce giant.
Oct 2, 2017 by Motley Fool StaffThe Path to Bankruptcy for Toys "R" UsThe one-time industry leader lost its way when other big box stores and online retailers ramped up competition for toys.
Oct 1, 2017 by Motley Fool StaffChipotle Is Hiring a "Top Chef" Winner to Boost Its Burger ConceptIf you’ve never heard of Tasty Made, the nascent chain Chipotle wants to develop, you’re not alone.
